Abstract
For decades, scholars believe major pharmaceutical corporations have been facing a decline in R&D efficiency, leading to an increasing demand for early-stage (R&D stage) external innovation. However, after outlining pharmaceutical corporations’ demands on external innovation toolkits by an inverse sigmoid curve, this research indicates an increasing focus of major players on late-stage (commercial or late-development stage) external innovation. Initial results deliver a potential strategy that transferring external innovation focus in advance for R&D excellence, and also suggests policy-makers provide further platforms for enhancing external innovation ecosystem in the pharmaceutical industry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
